Sun-Novo(SH:688621) Shang Hai Zheng Quan Bao·2025-08-08 20:11Fundraising Overview - The company has successfully raised a total of RMB 537.8 million through its initial public offering, with a net amount of RMB 467.18 million after deducting issuance costs [2] - The issuance involved 20 million shares at a price of RMB 26.89 per share, with a par value of RMB 1 per share [2] Fund Management - The company has established a management method for the use of raised funds, ensuring compliance with regulations from the China Securities Regulatory Commission and the Shanghai Stock Exchange [2] - A tripartite supervision agreement was signed with the sponsor and the bank managing the funds to clarify the rights and obligations of all parties involved [2] Account Closure - The company has closed certain special accounts for the raised funds as the related projects have been completed, transferring the remaining balances to other accounts [3] Major Asset Restructuring - The company is planning a major asset restructuring by issuing shares and convertible bonds to acquire 100% equity of Jiangsu Langyan Life Science Technology Holdings Co., Ltd [4] - This transaction is classified as a related party transaction since the target company is controlled by the company's major shareholder [4] Progress of the Restructuring - The company signed a letter of intent for the transaction on April 24, 2025, and subsequently suspended trading of its shares [5] - The board of directors approved the restructuring plan on May 12, 2025, and the company applied for the resumption of trading on May 13, 2025 [6] Ongoing Due Diligence - As of the latest announcement, the company is conducting audits, evaluations, and due diligence for the transaction, with further discussions on the transaction plan ongoing [7]